Researchers from Johns Hopkins are seeking to treat AMD with a single injection rather than multiple intra-ocular anti-VEGF injections.
The best way they found to do this was by using a common cold-like virus called AAV2 as a carrier of gene that activates the production of a different protein, sFLT01, to counter VEGF.
The clinical trial showed promising results, with the condition of four of the patients improving dramatically after just one viral injection. [T]he treatment didn’t produce any side effects in any patients, either. “Even at the highest dose, the treatment was quite safe. We found there were almost no adverse reactions in our patients,” said researcher Peter Campochiaro.
For more info: